Organization | Center for International Blood and Marrow Transplant Research

Center for International Blood and Marrow Transplant Research Report issue

Government Phase 2 Phase 3

Founded: Milwaukee WI United States (2004)

Organization Overview

First Clinical Trial

2004

NCT00785525

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2019

Timeline

NOW

Now

Alternative names

Center for International Blood and Marrow Transplant Research

Active Ingredients

Drugs in Phase 3 Trials (33)

allogeneic cord blood (2 trials)

allogeneic stem cells (1 trial)

allogenic autologous bone marrow ctl (1 trial)

autologous cd34+ cells (1 trial)

autologous hematopoietic cell (1 trial)

autologous mononuclear stem cell (3 trials)

autologous umbilical cord blood (1 trial)

bone marrow cells (1 trial)

bortezomib (velcade) (3 trials)

busulfan (myleran) (9 trials)

carmustine (bicnu) (2 trials)

cyclophosphamide (cytoxan) (16 trials)

cyclosporine (sandimmune) (2 trials)

etanercept (enbrel) (2 trials)

fluconazole (diflucan) (1 trial)

fludarabine (fludara) (15 trials)

lenalidomide (revlimid) (4 trials)

melphalan (alkeran) (6 trials)

methotrexate (1 trial)

mycophenolate (myfortic) (11 trials)

naltrexone (revia) (4 trials)

peripheral blood hematopoietic cell (2 trials)

prednisone (meticorten) (2 trials)

rituximab (rituxan) (2 trials)

ruxolitinib (jakafi) (1 trial)

sargramostim (leukine) (5 trials)

sirolimus (rapamune) (7 trials)

stem cells (1 trial)

tacrolimus (prograf) (9 trials)

thalidomide (Thalomid) (1 trial)

tositumomab (bexxar) (1 trial)

urea (2 trials)

voriconazole (vfend) (1 trial)

Drugs in Phase 2 Trials (20)

allogeneic bone marrow (1 trial)

allogeneic hematopoietic stem cells (Hemacord) (3 trials)

Anti-thymocyte Globulin (Rabbit) (Thymoglobulin) (4 trials)

bone marrow derived mesenchymal stem cells (1 trial)

cd33 car-t cells (1 trial)

cytarabine (cytosar-u) (1 trial)

dendritic cell tumor fusion vaccine (1 trial)

denileukin diftitox (ontak) (1 trial)

etoposide (vepesid) (2 trials)

filgrastim (neupogen) (3 trials)

haploidentical stem cell (1 trial)

hydroxyurea (hydrea) (1 trial)

ixazomib (ninlaro) (1 trial)

maraviroc (selzentry) (1 trial)

mesna (mesnex) (6 trials)

moxetumomab pasudotox (1 trial)

pentostatin (nipent) (1 trial)

plerixafor (mozobil) (1 trial)

thiotepa (2 trials)

tresulfan (1 trial)

Drugs in Other Trials (1)

whole blood (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Anemia (Phase 2)

Anemia, Aplastic (Phase 2)

Anemia, Sickle Cell (Phase 2)

Communicable Diseases (Phase 3)

Graft vs Host Disease (Phase 3)

Hodgkin Disease (Phase 2)

Immune System Diseases (Phase 3)

Infections (Phase 3)

Leukemia (Phase 3)

Leukemia, Biphenotypic, Acute (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 3)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 3)

Leukemia, Myeloid (Phase 3)

Leukemia, Myeloid, Acute (Phase 3)

Lymphoma (Phase 3)

Lymphoma, B-Cell (Phase 3)

Lymphoma, Follicular (Phase 3)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Lymphoma, Large-Cell, Immunoblastic (Phase 3)

Lymphoma, Non-Hodgkin (Phase 3)

Multiple Myeloma (Phase 3)

Mycoses (Phase 3)

Myelodysplastic-Myeloproliferative Diseases (Phase 3)

Myelodysplastic Syndromes (Phase 3)

Myeloproliferative Disorders (Phase 3)

Neoplasm, Residual (Phase 2)

Neoplasms, Plasma Cell (Phase 3)

Plasmablastic Lymphoma (Phase 3)

Pneumonia (Phase 3)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 3)

Preleukemia (Phase 3)

Syndrome (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 43
# of Trial APIs: 54